BioNTech SE
HealthcareNASDAQ:BNTX · NASDAQ Global Select
+$1.00 today
Vol 1.13M · Avg 0.99M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-5.7%
avg 25.0%
ROIC
-3.1%
avg 5.7%
ROA
-5.0%
avg 5.0%
Analysis
ROIC is currently the strongest return metric at -3.1% versus its period average of 5.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ugur Sahin | Co-Founder, Chief Executive Officer & Chair of the Management Board | $1.22M | — | 61 | $0.00 | <0.01% |
Ramon Zapata-Gomez | Chief Financial Officer & Member of Management Board | $1.18M | — | 52 | $18,879.00 | <0.01% |
Annemarie Hanekamp | Chief Commercial Officer & Member of Management Board | $1.03M | — | 46 | $0.00 | <0.01% |
James Timothy Patrick Ryan | Chief Legal & Business Officer and Member of the Management Board | $1.03M | — | 51 | $0.00 | <0.01% |
Sierk Pötting | MD, Chief Operating Officer & Member of Management Board | $1.00M | — | 53 | $0.00 | <0.01% |
Ozlem Tureci | Co-Founder, Chief Medical Officer & Member of Management Board | $970,102.00 | — | 59 | $0.00 | <0.01% |
Jasmina Alatovic | Vice President Corporate Communications | — | — | — | — | — |
Douglas Maffei | Vice President of Strategy & Investor Relations | — | — | — | — | — |
Kylie Jimenez | Chief People Officer & Member of Management Board | — | — | 50 | $10,488.00 | <0.01% |
Lisa Birringer | Senior Vice President of Global Financial Reporting & Accounting | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$5.53M
Net Sentiment
$5.53M
Net selling
Most Active
Poetting Sierk
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $5.53M over the last 12 months. That adds up to net selling of $5.53M. Poetting Sierk was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +429.8% | -18.1% (9yr)13 analysts |
| Net Income | N/A | N/A | N/A | N/A13 analysts |
| EBIT | N/A | N/A | N/A | -27.3% (9yr)13 analysts |
Analysis
Recent growth has been strongest in Revenue at +429.8% over three years. Forward estimates point to Revenue at -18.1% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Teva Pharmaceutical Industries Limited
NYSE:TEVA
$40.32B
Natera, Inc.
NASDAQ:NTRA
$30.37B
Biogen Inc.
NASDAQ:BIIB
$29.53B
DexCom, Inc.
NASDAQ:DXCM
$29.08B
Koninklijke Philips N.V.
NYSE:PHG
$25.70B
Royalty Pharma plc
NASDAQ:RPRX
$23.60B
United Therapeutics Corporation
NASDAQ:UTHR
$23.17B
Incyte Corporation
NASDAQ:INCY
$21.68B
STERIS plc
NYSE:STE
$20.26B
Genmab A/S
NASDAQ:GMAB
$15.40B
Who manages BNTX?
BioNTech SE (BNTX) lists 10 active executives. The top listed executive is James Timothy Patrick Ryan, Chief Legal & Business Officer and Member of the Management Board.
Are BNTX insiders buying or selling?
Recent insider activity shows net selling of $5.53M.
Explore More
Continue the stock analysis
Jump to another research area for this company.